Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC

Inclusion Criteria: * Histologically or cytologically proven diagnosis of NSCLC that is locally advanced or metastatic. * Positive for translocation or inversion events involving the ROS1 gene as determined by protocol defined test. * ECOG performance status 0 to 2. * Adequate organ function * Patients with brain metastases are eligible if neurologically stable for at least 2 weeks and have no ongoing requirement for corticosteroids. * Male patients able to father children and female patients of childbearing potential and at risk for pregnancy must agree to use 2 highly effective methods of contraception throughout the study and for at least 90 days after the last dose of crizotinib. Exclusion Criteria: * Currently receiving crizotinib or any investigational products. * Prior therapy specifically directed against ROS1 fusion genes including crizotinib. * Carcinomatous meningitis or leptomeningeal disease. * Spinal cord compression unless treated with the patient attaining good pain control and stable or recovered neurologic function. * Ongoing uncontrolled congestive heart failure (CHF) and any of the following within the 3 months prior to starting study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, or cerebrovascular accident including transient ischemic attack. * Ongoing cardiac dysrhythmias of CTCAE Grade 2, uncontrolled atrial fibrillation of any grade, or QTc more than 480 msec. * History of extensive disseminated/bilateral or known presence of Grade 3 or 4 interstitial fibrosis or interstitial lung disease, including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis, but not history of prior radiation pneumonitis. * Pregnant female patients; breastfeeding female patients. * Use of drugs or foods including known potent CYP3A4 inhibitors, known potent CYP3A4 inducers and CYP3A4 substrates with narrow therapeutic indices